Ironwood candidate stalls in gastroparesis

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it is discontinuing development of IW-9179 to treat diabetic gastroparesis after the guanylate cyclase C ( GCC; GUCY2C) agonist "did not meaningfully reduce the severity of symptoms" in a Phase IIa trial.

The study enrolled 90 patients who received IW-9179 or placebo, once or twice daily for four weeks. Efficacy was evaluated by "multiple patient assessments of cardinal symptoms associated with gastroparesis." IW-9179 was generally well-tolerated, with diarrhea the most common adverse event. ...